Quick Answer
Moleculin Biotech, Inc. reported Operating Income of -$25.10 million for fiscal year 2025.
Moleculin Biotech, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$25.10M | +5.8% |
| 2024 | -$26.64M | +10.1% |
| 2023 | -$29.63M | +3.3% |
| 2022 | -$30.64M | -33.4% |
| 2021 | -$22.97M | -16.3% |
| 2020 | -$19.74M | -12.7% |
| 2019 | -$17.52M | -16.6% |
| 2018 | -$15.03M | -73.6% |
| 2017 | -$8.65M | -122.8% |
| 2016 | -$3.88M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.91M | +17.2% | -3.3% |
| June 30, 2025 | -$5.72M | +7.5% | +3.8% |
| March 31, 2025 | -$5.94M | +11.0% | +16.7% |
| September 30, 2024 | -$7.13M | -20.0% | -15.4% |
| June 30, 2024 | -$6.18M | +3.5% | +7.4% |
| March 31, 2024 | -$6.68M | +20.1% | -12.3% |
| September 30, 2023 | -$5.95M | +34.5% | +7.2% |
| June 30, 2023 | -$6.41M | +13.8% | +23.3% |
- Moleculin Biotech, Inc. showed an increase of +5.8% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, Moleculin Biotech, Inc.’s operating income has declined by 546.5% (from -$3.88 million to -$25.10 million).
- The most recent figure is from Moleculin Biotech, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: